REWIND, DECLARE, and high-risk diabetes patients | diabetes.medicinematters.com
Skip to main content

Home

Latest news

Browse topics

Cardiovascular disorders
Chronic kidney disease
Diabetes devices & technology
GLP-1 receptor agonists
Hyperglycemia
Hypoglycemia
Obesity, diet, & lifestyle interventions
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Browse all topics
EN
EN

In focus

Fasting for religion and health in people with diabetes
The challenge of type 2 diabetes in children
HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved
Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice
The SURPASS trials: Summarizing efficacy data on tirzepatide
Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
Why psychosocial care matters
DiRECT: Type 2 diabetes remission through weight management

Congress coverage

EASD 58th Annual Meeting 2022
The American Diabetes Association 82nd Scientific Sessions

About us

Medicine Matters Diabetes
EXTENDED SEARCH
Log in
Top

07-02-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

share
SHARE
print
PRINT
insite
SEARCH

LISTEN: How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti (9:04).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

share
SHARE
print
PRINT

Related content

06-10-2019 | Dulaglutide | ADA 2019 | News

Dulaglutide cardioprotective in relatively low-risk REWIND population

06-10-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: A nurse educator’s view of the REWIND trial

06-13-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

04-17-2018 | DPP-4 inhibitors | At a glance | Article

Round-up of the DPP-4 inhibitor CV outcome trials
Image Credits